Abstract
e18056 Background: Although induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) is recommended as standard treatment option of locally advanced nasopharyngeal carcinoma (NPC), the IC regimens conduct further study. Therefore, this study was evaluated the efficacy and safety of IC with nab-paclitaxel and nedaplatin followed by CCRT in locally advanced NPC. Methods: In this retrospective real-world study, 295 patients was enrolled, and all received nab-paclitaxel (260mg/m2/d) and nedaplatin (80mg/m2/d) –based IC every 3 weeks. Results: All patients completed the treatment plans. The ORR were 95.3% in the NP and 96.9% in the neck after IC, respectively. At the end of CCRT, the ORR were 97.3% in the NP and 97.3% in the neck nodes, respectively. 3 years survival outcomes were 96.4% of OS, 95.7% of LRRFS, 93.7% of DMFS, and 89.8% of PFS, respectively. During IC, all treatment-related adverse events occurred in 43.2%. The most frequent grade 3 toxicities were neutropenia (7.8%), leucopenia (4.4%), anaemia (0.3%), thrombopenia (2.4%) and hepatic injury (3.1%), respectively. Conclusions: IC with nab-paclitaxel and nedaplatin showed promising efficacy and safety profile in locally advanced NPC.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call